Janet Markle

Assistant Professor

Vanderbilt University Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Janet Markle is an Assistant Professor at Vanderbilt University Medical Center in the United States. Her research focuses on immunology and inflammatory diseases, with recent publications addressing topics such as neonatal onset multisystem inflammatory disease, BCL10 deficiency, c-Rel deficiency, and the role of T-bet in immunity against mycobacteria. Professor Markle's work contributes to the understanding of immune system disorders and their clinical implications.

Articles (7)

Background Primary amoebic meningoencephalitis (PAM) is a rapidly progressive and often fatal central nervous system infection caused by Naegleria fowleri . Despite widespread environmental exposure to this free-living amoeba, clinical disease is rare, suggesting that it requires not only exposure to the amoeba but also a host vulnerability. Yet, the immune mechanisms controlling protection vs. susceptibility to N. fowleri remain poorly understood. Methods We conducted comprehensive clinical, immunological, and genetic investigations in one of the few survivors of PAM. We performed high-dimensional immune profiling using Cytometry by Time-Of-Flight (CyTOF) to assess immune cell composition and activation state. We employed whole-exome sequencing (WES) to identify rare genetic variants that affect host responses. Functional immune assays were used to assess serum-mediated amoebicidal activity in vitro and to characterize key host defense pathways. Results A previously healthy pediatric patient was diagnosed with PAM. Contrary to other cases, her clinical course lasted for more than 2 months before she recovered with miltefosine treatment. Immunologic evaluation showed this patient had normal numbers and frequencies of major lymphoid and myeloid immune cells. WES revealed a homozygous deletion in the complement component 2 (C2) gene, resulting in a complete absence of circulating C2 protein and abolishing classical complement pathway activity. Normal human serum induced complement-mediated lysis of N. fowleri trophozoites in vitro, whereas complement-depleted normal human serum and serum from our patient both failed to deposit membrane attack complex (MAC) or kill N. fowleri . MAC deposition and amoebicidal activity were restored by supplementing the patient’s serum with purified human C2 protein. Conclusion Our study demonstrates that PAM can be caused by a monogenic inborn error of immunity (IEI) and that the complement system is critical for human immunity against Naegleria fowleri .

Year:

2026

Cook et al. report a novel de novo heterozygous N236K mutation in PSTPIP1, identified in a patient with neonatal-onset PAMI that was ultimately fatal. The N236K mutation showed increased binding to pyrin and enhanced inflammasome formation. The authors also identify blood transcriptome changes in PAMI patients with both N236K and the more common E250K mutation.

Year:

2026

Background G6PC3 deficiency is a rare genetic disorder that causes syndromic congenital neutropenia. It is driven by the intracellular accumulation of a metabolite named 1,5-anhydroglucitol-6-phosphate (1,5-AG6P) that inhibits glycolysis. Patients display heterogeneous extra-hematological manifestations, contributing to delayed diagnosis. Objective The G6PC3 c.210delC variant has been identified in patients of Mexican origin. We set out to study the origin and functional consequence of this mutation. Furthermore, we sought to characterize the clinical phenotypes caused by it. Methods Using whole-genome sequencing data, we conducted haplotype analysis to estimate the age of this allele and traced its ancestral origin. We examined how this mutation affected G6PC3 protein expression and performed extracellular flux assays on patient-derived cells to characterize how this mutation impacts glycolysis. Finally, we compared the clinical presentations of patients with the c.210delC mutation relative to other G6PC3 deficient patients published to date. Results Based on the length of haplotypes shared amongst ten carriers of the G6PC3 c.210delC mutation, we estimated that this variant originated in a common ancestor of indigenous American origin. The mutation causes a frameshift that introduces a premature stop codon, leading to a complete loss of G6PC3 protein expression. When treated with 1,5-anhydroglucitol (1,5-AG), the precursor to 1,5-AG6P, patient-derived cells exhibited markedly reduced engagement of glycolysis. Clinically, c.210delC carriers display all the clinical features of syndromic severe congenital neutropenia type 4 observed in prior reports of G6PC3 deficiency. Conclusion The G6PC3 c.210delC is a loss-of-function mutation that arose from a founder effect in the indigenous Mexican population. These findings may facilitate the diagnosis of additional patients in this geographical area. Moreover, the in vitro 1,5-AG-dependent functional assay used in our study could be employed to assess the pathogenicity of additional G6PC3 variants.

Year:

2024

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (10)

Ruben Martinez Barricarte

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Rebeca Perez de Diego

Fundación para la Investigación Biomédica del Hospital Universitario La Paz

SPAIN
View details

Luis Ignacio Gonzalez-Granado

F.E.A

Universidad Complutense de Madrid

SPAIN
View details

Andrew Patterson

Assistant Professor

University of Louisville

UNITED STATES
View details

James Connelly

Vanderbilt University Medical Center

UNITED STATES
View details

Mariana Byndloss

Associate Professor

Vanderbilt University Medical Center

UNITED STATES
View details

David Langlais

Associate Professor / Principal Investigator

McGill University

CANADA
View details

Eric Gamazon

University of Chicago

UNITED STATES
View details

qiang pan-hammarstrom

Professor, head of the Immunology Division

Karolinska University Hospital

SWEDEN
View details

Jeffrey C. Rathmell

Chair and Professor

University of Chicago

UNITED STATES
View details